Institution
University of Alberta
Education•Edmonton, Alberta, Canada•
About: University of Alberta is a education organization based out in Edmonton, Alberta, Canada. It is known for research contribution in the topics: Population & Health care. The organization has 65403 authors who have published 154847 publications receiving 5358338 citations. The organization is also known as: Ualberta & UAlberta.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A personal perspective about the development of the seminal papers associated with the Community of Inquiry Framework is provided and the evolution of the framework and its associated methodology is explored.
Abstract: This article provides a personal perspective about the development of the seminal papers associated with the Community of Inquiry Framework. The framework and its construction are described. The main part of the paper explores the evolution of the framework and its associated methodology. Finally, research associated with the validation of the framework and new research directions are reviewed.
847 citations
••
845 citations
••
University of California, San Francisco1, Harvard University2, Hoffmann-La Roche3, Ohio State University4, Indiana University – Purdue University Indianapolis5, University of Alberta6, Emory University7, University of California, Los Angeles8, Lund University9, University of Alabama at Birmingham10, University of Gothenburg11
TL;DR: Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α chain of the interleukin-2 receptor and may thus reduce the risk of rejection after renal transplantation.
Abstract: Background Monoclonal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive T lymphocytes may cause selective immunosuppression. Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α chain of the interleukin-2 receptor and may thus reduce the risk of rejection after renal transplantation. Methods We administered daclizumab (1.0 mg per kilogram of body weight) or placebo intravenously before transplantation and once every other week afterward, for a total of five doses, to 260 patients receiving first cadaveric kidney grafts and immunosuppressive therapy with cyclosporine, azathioprine, and prednisone. The patients were followed at regular intervals for 12 months. The primary end point was the incidence of biopsy-confirmed acute rejection within six months after transplantation. Results Of the 126 patients given daclizumab, 28 (22 percent) had biopsy-confirmed episodes of acute rejection, as compared with 47 of the ...
845 citations
••
TL;DR: A quantitative bioeconomic modelling framework is presented to analyse risks from non–indigenous species to economic activity and the environment, and it is shown that society could benefit by spending up to US$324 000 year−1 to prevent invasions into a single lake with a power plant.
Abstract: Numbers of non-indigenous species--species introduced from elsewhere - are increasing rapidly worldwide, causing both environmental and economic damage. Rigorous quantitative risk-analysis frameworks, however, for invasive species are lacking. We need to evaluate the risks posed by invasive species and quantify the relative merits of different management strategies (e.g. allocation of resources between prevention and control). We present a quantitative bioeconomic modelling framework to analyse risks from non-indigenous species to economic activity and the environment. The model identifies the optimal allocation of resources to prevention versus control, acceptable invasion risks and consequences of invasion to optimal investments (e.g. labour and capital). We apply the model to zebra mussels (Dreissena polymorpha), and show that society could benefit by spending up to US$324 000 year(-1) to prevent invasions into a single lake with a power plant. By contrast, the US Fish and Wildlife Service spent US$825 000 in 2001 to manage all aquatic invaders in all US lakes. Thus, greater investment in prevention is warranted.
845 citations
••
Saint Louis University1, University of Barcelona2, University of Alberta3, University of Erlangen-Nuremberg4, Boston University5, Uppsala University Hospital6, University of East Anglia7, University of California, San Francisco8, Duke University9, Western General Hospital10, National Institutes of Health11, Tufts University12, Kagoshima University13, University of California, Los Angeles14, SOCAR15, University of Cagliari16, Sapienza University of Rome17, Tufts Medical Center18, Tampa General Hospital19, University of Toulouse20, Charité21, Stony Brook University Hospital22
TL;DR: It is concluded that "Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition.
845 citations
Authors
Showing all 66027 results
Name | H-index | Papers | Citations |
---|---|---|---|
Salim Yusuf | 231 | 1439 | 252912 |
Yi Chen | 217 | 4342 | 293080 |
Robert M. Califf | 196 | 1561 | 167961 |
Douglas R. Green | 182 | 661 | 145944 |
Russel J. Reiter | 169 | 1646 | 121010 |
Jiawei Han | 168 | 1233 | 143427 |
Jaakko Kaprio | 163 | 1532 | 126320 |
Tobin J. Marks | 159 | 1621 | 111604 |
Josef M. Penninger | 154 | 700 | 107295 |
Subir Sarkar | 149 | 1542 | 144614 |
Gerald M. Edelman | 147 | 545 | 69091 |
Rinaldo Bellomo | 147 | 1714 | 120052 |
P. Sinervo | 138 | 1516 | 99215 |
David A. Jackson | 136 | 1095 | 68352 |
Andreas Warburton | 135 | 1578 | 97496 |